Compass Capital Management Inc. Acquires 3,100 Shares of AbbVie Inc. $ABBV

Compass Capital Management Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 387.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,900 shares of the company’s stock after acquiring an additional 3,100 shares during the quarter. Compass Capital Management Inc.’s holdings in AbbVie were worth $1,020,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in ABBV. State Street Corp raised its position in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares during the period. Fisher Asset Management LLC grew its position in shares of AbbVie by 252.6% in the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares during the period. Legal & General Group Plc acquired a new stake in shares of AbbVie in the second quarter valued at about $2,905,952,000. Finally, Deutsche Bank AG increased its stake in shares of AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.2%

Shares of ABBV opened at $295.18 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93. The stock has a market cap of $521.76 billion, a PE ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. The firm’s fifty day moving average is $275.51 and its two-hundred day moving average is $240.91.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.86 earnings per share. As a group, research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is currently 125.30%.

Key Stories Impacting AbbVie

Here are a few of the latest stories about ABBV:

  • Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
  • Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
  • Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Analyst Upgrades and Downgrades

ABBV has been the subject of several research analyst reports. Scotiabank upped their price target on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $275.00 price objective on shares of AbbVie in a report on Monday, November 2nd. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. Argus boosted their price objective on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Finally, Rothschild & Co Redburn increased their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $297.46.

View Our Latest Report on AbbVie

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

AbbVie Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.